# Individual Patient Expanded Access-Glembatumumab Vedotin

> **NCT03067935** · — · NO_LONGER_AVAILABLE · sponsor: **Celldex Therapeutics**

## Conditions studied

- Metastatic gpNMB Expressing Triple Negative Breast Cancer

## Interventions

- **DRUG:** glembatumumab vedotin

## Key facts

- **NCT ID:** NCT03067935
- **Lead sponsor:** Celldex Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2018-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03067935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03067935, "Individual Patient Expanded Access-Glembatumumab Vedotin". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03067935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*